Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-07.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101 A Case of Bezafibrate induced Rhabdomyolysis.
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism



Page Path
HOME > Endocrinol Metab > Volume 15(4-5); 2000 > Article
Case Report A Case of Bezafibrate induced Rhabdomyolysis.
Won Yong Shin, Sung Hun Kim, Jae Suk Jeon, Kyong Wan Min, Kyong Ah Han, Eung Jin Kim
Endocrinology and Metabolism 2000;15(4-5):634-639

Published online: January 1, 2001
  • 17 Download
  • 0 Crossref
  • 0 Scopus
Department of Internal Medicine, Eul Ji Hospital, Eul Ji University School of Medicine, Seoul Korea.

Bezafibrate, a fibric acid derivative related to clofibrate, is being used increasingly in the treatment of hypertriglycemia. It is relatively well tolerated at usual dosage, and has a low incidence of adverse reactions. But we had recently observed a reversible deterioration of renal function requiring hemodialysis, presumed to be caused by bezafibrate treatment in a patient with diabetic nephropathy. A 55 year old man was admitted with complaints of general weakness and painful lower extremities. He had taken bezafibrate (200 mg every 12 hours) for the previous 4 months because of hypertriglycemia. After admission, the drug was withdrawn, and he was treated conservatively management with hydration and diuretics for bezafibrate induced rhabdomyolysis. Nevertheless, his symptom was not improved, so he was taken even hemodialysis. These findings suggested that bezafibrate should be admistered with great caution to patient with renal insufficiency. When it is admistered, CK, LDH, aldolase, and sGOT levels have to be checked for early detection of potential side effect.

Related articles

Endocrinol Metab : Endocrinology and Metabolism